Updated hourlyHourly refreshSun, Oct 25, 2026
Press Release Database
Recent press releases, indexed by topic.
Finance · Healthcare
ROCKVILLE, MD, Oct. 23, 2026 -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced positive interim data from its Phase 1 study evaluating MGC026, a B7-H3-directed antibody-drug conjugate (ADC), in patients with advanced solid tumors. These Phase 1 data were presented today at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain. These results demonstrated durable activity across a broad range of solid tumors, which the Company believes supports expanded development of MGC026 in front-line metastatic squamous cell carcinoma of the head and neck (SCCHN) in combination with pembrolizumab.
Oct 23 · 13:15·GlobeNewswire
Healthcare · Biotech & pharma
Identify cost-saving trial locations, guide investment strategies, uncover business opportunities, and benchmark trial success, enrollment trends and competitors.
Identify cost-saving trial locations, guide investment strategies, uncover business opportunities, and benchmark trial success, enrollment trends and competitors.
Oct 23 · 13:14·GlobeNewswire
Healthcare · Biotech & pharma
Optimize trial ROI by identifying cost efficient locations, enrollment trends, success rates and key opportunities to sharpen investment strategies and gain a competitive edge.
Optimize trial ROI by identifying cost efficient locations, enrollment trends, success rates and key opportunities to sharpen investment strategies and gain a competitive edge.
Oct 23 · 13:13·GlobeNewswire
Healthcare · Biotech & pharma
Identify efficient trial locations, investment opportunities and competitive strategies using global trial, enrollment, sponsor and success rate insights.
Identify efficient trial locations, investment opportunities and competitive strategies using global trial, enrollment, sponsor and success rate insights.
Oct 23 · 13:11·GlobeNewswire
Healthcare · Biotech & pharma
Identify strategic trial locations to save time and cost, uncover business opportunities, guide investments and benchmark enrollment trends, success rates and competitors.
Identify strategic trial locations to save time and cost, uncover business opportunities, guide investments and benchmark enrollment trends, success rates and competitors.
Oct 23 · 13:10·GlobeNewswire
Healthcare · Biotech & pharma
Identify cost-saving trial locations, investment opportunities, enrollment trends and success rates to sharpen strategy and gain competitive advantage.
Identify cost-saving trial locations, investment opportunities, enrollment trends and success rates to sharpen strategy and gain competitive advantage.
Oct 23 · 13:09·GlobeNewswire
Healthcare · Biotech & pharma
ESMO 2026 abstracts featuring FCS research: 52P, 1017P, 1076TiP, 1021P, 1134eTiP, 1146eTiP, 1594P, 1846P, 3151P, 2216O FORT MYERS, Fla., Oct. 23, 2026 -- Findings from early-phase clinical research conducted with participation from Florida Cancer Specialists & Research...
Oct 23 · 13:08·PR Newswire
Healthcare · Biotech & pharma
Identify high-potential trial locations, reduce time and costs, guide investment strategies, uncover business opportunities and strengthen competitive advantage.
Identify high-potential trial locations, reduce time and costs, guide investment strategies, uncover business opportunities and strengthen competitive advantage.
Oct 23 · 13:08·GlobeNewswire
Finance · SaaS
REDWOOD CITY, Calif., Oct. 23, 2026 -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT) (“Bolt” or the “Company”) today announced the acquisition of Prana Therapies, Inc. (“Prana”), a clinical-stage biotechnology company pioneering next-generation half-life-extended multispecific antibodies designed to deliver best-in-disease therapies. Following the acquisition, the Company will focus on advancing Prana’s pipeline of half-life-extended multispecific antibodies generated from its proprietary INSPIRE platform, led by PRA-216, a novel IL-4Rα/TSLP bispecific antibody currently in Phase 2 development in asthma, chronic obstructive pulmonary disease (COPD) and atopic dermatitis, with a Phase 2 study in eosinophilic esophagitis (EoE) planned.
Oct 23 · 13:08·GlobeNewswire
AI · Biotech & pharma
Preliminary cash, including short-term deposits, of approximately $11.0 million as of September 30, 2026, and total liabilities of approximately $2.5 million
Oct 23 · 13:06·GlobeNewswire
Finance · Healthcare
NASHVILLE, Tenn., Oct. 23, 2026 -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), an innovation-driven biopharmaceutical company advancing new therapies that address significant unmet medical needs, confirmed that it will provide an update on its ifetroban product candidate...
Oct 23 · 13:05·PR Newswire
Finance · Healthcare
BOSTON, Oct. 23, 2026 -- Elicio Therapeutics, Inc. (Nasdaq: ELTX) (“Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced results from the randomized Phase 2 AMPLIFY-7P study of camupepimut (ELI-002 7P), presented in a late-breaking Proffered Paper oral session at the European Society for Medical Oncology (“ESMO”) Congress 2026 in Madrid, Spain, and simultaneously published in Nature Medicine: "Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic cancer: the randomized phase 2 AMPLIFY-7P trial".
Oct 23 · 13:00·GlobeNewswire